Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · September 24, 2024

Assessing the Clinical Similarity of SB17 — a Proposed Ustekinumab Biosimilar — to Reference Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis

Journal of the American Academy of Dermatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the American Academy of Dermatology
A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis
J Am Acad Dermatol 2024 Sep 01;91(3)440-447, SR Feldman, J Narbutt, G Girolomoni, J Brzezicki, N Reznichenko, MA Zegadło-Mylik, G Pulka, M Dmowska-Stecewicz, E Kłujszo, D Rekalov, L Rajzer, J Lee, M Lee, YH Rho

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading